Drug Approval | August 05, 2021
Combinations of Sputnik V component with other vaccines demonstrate favourable results: RDIF
AstraZeneca, Sinopharm and Moderna were part of the study
AstraZeneca, Sinopharm and Moderna were part of the study
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The drug is used with other HIV medications to help control HIV infection and it helps to decrease the amount of HIV in one’s body so that the immune system can work better
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
Subscribe To Our Newsletter & Stay Updated
